Education
About Us
Working with TipRanks
Follow Us
3SBio, Inc. (HK:1530)
:1530
1530 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$5.47 - HK$31.70
Previous CloseN/A
Volume7.16M
Average Volume (3M)41.79M
Market Cap
HK$72.95B
Enterprise ValueHK$50.35B
Total Cash (Recent Filing)HK$5.79B
Total Debt (Recent Filing)¥3.55B
Price to Earnings (P/E)30.5
Beta0.98
Next Earnings
Aug 20, 2025EPS Estimate
0.56Last Dividend Ex-Date
Jul 21, 2025Dividend Yield0.03%
Share Statistics
EPS (TTM)0.46
Shares Outstanding2,399,586,400
10 Day Avg. Volume44,561,928
30 Day Avg. Volume41,789,526
Financial Highlights & Ratios
PEG Ratio1.00
Price to Book (P/B)3.35
Price to Sales (P/S)0.00
P/FCF Ratio57.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$24.10Price Target Upside-20.73% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
3SBio News
PremiumCompany Announcements
3SBio and Pfizer Finalize License Agreement and Share Subscription
PremiumCompany Announcements
3SBio Inc. Announces AGM Results, Dividend Payment, and Committee Changes
PremiumCompany Announcements
3SBio Announces Board Roles and Functions
PremiumCompany Announcements
3SBio Inc. Updates Nomination Committee Terms of Reference
PremiumCompany Announcements
3SBio Inc. Announces Annual General Meeting with Key Resolutions
PremiumCompany Announcements
3SBio Partners with Pfizer for Global Licensing of Oncology AntibodyPremiumCompany Announcements
3SBio’s 707 Injection Receives Breakthrough Therapy Designation in ChinaBulls Say, Bears Say
Bulls Say
Product PerformanceTPIAO's sales increased 20.4% YoY to RMB5.1bn, becoming the leading drug in China's thrombocytopenia treatment market, with stable pricing and increasing penetration.
Revenue Growth3SBio delivered a strong performance with revenue increasing 16.5% YoY to RMB9.1bn, driven by the robust growth of TPIAO, Mandi and other products.
Strategic Expansion3SBio has expanded its pipeline through strategic in-licensing, acquiring four key assets, including Paclitaxel Oral Solution which has received NMPA approval.
Bears Say
Dividend Payout3SBio has declared a final dividend of HK$0.25/shares, for a payout ratio of ~29%.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
4.57%
Mutual Funds
― Other Institutional Investors
91.65% Public Companies and
Individual Investors
1530 FAQ
What was 3SBio, Inc.’s price range in the past 12 months?
3SBio, Inc. lowest stock price was HK$5.47 and its highest was HK$31.70 in the past 12 months.
What is 3SBio, Inc.’s market cap?
3SBio, Inc.’s market cap is HK$72.95B.
When is 3SBio, Inc.’s upcoming earnings report date?
3SBio, Inc.’s upcoming earnings report date is Aug 20, 2025 which is in 25 days.
How were 3SBio, Inc.’s earnings last quarter?
3SBio, Inc. released its earnings results on Mar 25, 2025. The company reported HK$0.455 earnings per share for the quarter, missing the consensus estimate of HK$0.472 by -HK$0.016.
Is 3SBio, Inc. overvalued?
According to Wall Street analysts 3SBio, Inc.’s price is currently Overvalued.
Does 3SBio, Inc. pay dividends?
3SBio, Inc. pays a Annually dividend of HK$0.25 which represents an annual dividend yield of 0.03%. See more information on 3SBio, Inc. dividends here
What is 3SBio, Inc.’s EPS estimate?
3SBio, Inc.’s EPS estimate is 0.56.
How many shares outstanding does 3SBio, Inc. have?
3SBio, Inc. has 2,399,586,400 shares outstanding.
What happened to 3SBio, Inc.’s price movement after its last earnings report?
3SBio, Inc. reported an EPS of HK$0.455 in its last earnings report, missing expectations of HK$0.472. Following the earnings report the stock price went down -7.617%.
Which hedge fund is a major shareholder of 3SBio, Inc.?
Currently, no hedge funds are holding shares in HK:1530
3SBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$24.10 (-20.73% Downside)
HK$24.10 (-20.73% Downside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
387.50%
12-Months-Change
Fundamentals
Return on Equity
14.19%
Trailing 12-Months
Asset Growth
-0.42%
Trailing 12-Months
Company Description
3SBio, Inc.
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and DanaFarber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
1530 Stock 12 Month Forecast
Average Price Target
HK$24.10
▼(-20.73%Downside)
Technical Analysis
Sino Biopharmaceutical
―
Innovent Biologics
―
Wuxi Biologics (Cayman)
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―